Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan.

MLA

Koga, Tomohiro, et al. “Anti-Citrullinated Peptide Antibodies Are the Strongest Predictor of Clinically Relevant Radiographic Progression in Rheumatoid Arthritis Patients Achieving Remission or Low Disease Activity: A Post Hoc Analysis of a Nationwide Cohort in Japan.” PLoS ONE, vol. 12, no. 5, May 2017, pp. 1–13. EBSCOhost, https://doi.org/10.1371/journal.pone.0175281.

APA

Koga, T., Okada, A., Fukuda, T., Hidaka, T., Ishii, T., Ueki, Y., Kodera, T., Nakashima, M., Takahashi, Y., Honda, S., Horai, Y., Watanabe, R., Okuno, H., Aramaki, T., Izumiyama, T., Takai, O., Miyashita, T., Sato, S., Kawashiri, S., & Iwamoto, N. (2017). Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan. PLoS ONE, 12(5), 1–13. https://doi.org/10.1371/journal.pone.0175281

Chicago

Koga, Tomohiro, Akitomo Okada, Takaaki Fukuda, Toshihiko Hidaka, Tomonori Ishii, Yukitaka Ueki, Takao Kodera, et al. 2017. “Anti-Citrullinated Peptide Antibodies Are the Strongest Predictor of Clinically Relevant Radiographic Progression in Rheumatoid Arthritis Patients Achieving Remission or Low Disease Activity: A Post Hoc Analysis of a Nationwide Cohort in Japan.” PLoS ONE 12 (5): 1–13. doi:10.1371/journal.pone.0175281.